https://www.horizonscangeneesmiddelen.nl/nieuws/opheffing-sluis-voor-briumvi-ublituximab-en-vabysmo-faricimab
Opheffing sluis voor Briumvi (ublituximab) en Vabysmo (faricimab) | Horizonscan geneesmiddelen
Betreft een wijziging van de Regeling zorgverzekering in verband met de opname van Briumvi (ublituximab) en Vabysmo (faricimab) in het basispakket.
horizonscan geneesmiddelensluisvoorublituximab
https://checkorphan.org/clinicaltrial/lenalidomide-umbralisib-and-ublituximab-for-the-treatment-of-relapsed-or-refractory-indolent-non-hodgkin-lymphoma-or-mantle-cell-lymphoma/
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent...
for thelenalidomideublituximabtreatmentrefractory
https://prescriberpoint.com/therapies/briumvi-3a77cd8
Briumvi (ublituximab) - Dosing, PA Forms & Info (2026)
ublituximabdosingpaformsinfo
https://digitalcommons.providence.org/publications_2/106/
"Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Ope" by Bruce A C Cree, Edward...
Importance: In the 2-year Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (ULTIMATE) I and II...
five yearsmultiple sclerosisublituximabultimateii